Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-12-22 Capital/Financing Update
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - MSB 5 pages 28.8KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Mesoblast Limited regarding a proposed issue of securities, specifically a placement of new options (ADS Warrants 2). It details the number of securities, issue date, terms, and regulatory compliance with ASX listing rules. There are no financial statements or detailed financial performance data included, and the document is focused on informing about the capital raising activity. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes.
2022-12-22 English
Extension of Undrawn US$30 million Facility 2 pages 160.1KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the extension of availability of undrawn tranches of a financing facility between Mesoblast and Oaktree Capital Management. It details the terms of the financing facility, including amounts, interest rates, milestone conditions, and warrants issuance. There is no financial statement data, no detailed financial performance, no regulatory filing or certification, and no mention of an annual or interim report. The content focuses on financing activity and capital structure update. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is 6911 characters, which is sufficient for a substantive announcement rather than a brief notice or report publication announcement.
2022-12-22 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
Regulatory Filings
2022-12-20 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
Regulatory Filings
2022-12-20 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
Regulatory Filings
2022-12-20 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
Regulatory Filings
2022-12-20 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.